- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
Ligand id: 6941
View more information in the IUPHAR Pharmacology Education Project: obinutuzumab
|Approved drug?||Yes (FDA (2013), EMA (2014))|
|International Nonproprietary Names|
|GA-101 | GA101 | Gazyva®|
|Obinutuzumab is a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb. Prior to 2009 obinutuzumab was known as afutuzumab.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
|GtoPdb PubChem SID||178103523|
|Search PubMed clinical trials||obinutuzumab|
|Search PubMed titles||obinutuzumab|
|Search PubMed titles/abstracts||obinutuzumab|